PTC Therapeutics and Eli Lilly acquire Sangamo assets in bankruptcy auction
Bankrupt gene editing biotech Sangamo is selling parts of its business to PTC Therapeutics and Eli Lilly for up to $264 million following an auction. The deal involves the acquisition of specific assets from the struggling company. The transaction highlights the ongoing consolidation in the gene editing sector.
Related stories
Khartis Therapeutics Secures $50M Series B for Thyroid Eye Disease Treatment · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “PTC Therapeutics, Lilly to buy up bits of Sangamo in bankruptcy auction.” Browse more stories.